Insight

William Oh: Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go

William Oh/Linkedin

Dec 2, 2023, 16:55

William Oh: Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go

William Oh, Chief Medical Officer at the Prostate Cancer Foundation (PCF), shared on LinkedIn:

“MSK-IMPACT has been a key single source of data regarding the growing influence of precision medicine in cancer. From 2017- 2022, an increase was noted from 8.9% to 31.6% in the fraction of tumors harboring a standard care (Level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying non-actionable drivers (44.2% to 22.8%). Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go.”

For the article click here.
Source: William Oh/LinkedIn

cancer Memorial Sloan Kettering Cancer Center (MSK) MSK-IMPACT OncoDaily Oncology Precision Medicine Prostate Cancer Foundation Target therapy William Oh

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer